

Panacea Biotec

Innovation in support of life

27th August, 2018

The Manager, Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Fax No.:022-26598237 / 38
NSE Symbol: PANACEABIO

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
Fax No.:022-22721919, 3121
BSE Scrip Code: 531349

Re.: Press Release - Panacea Biotec Ltd. inks Tripartite Agreement with Natco Pharma Ltd. & Breckenridge Pharmaceutical Inc., for manufacturing and supply of Azacitidine injection in the U.S. market

Dear Sir,

Panacea Biotec Ltd. (“Panacea Biotec”) is pleased to announce that the Company has entered into a tripartite agreement with Natco Pharma Ltd. (“Natco”) and Breckenridge Pharmaceutical Inc. (“Breckenridge”) for the manufacture and supply of Azacitidine Injection for the U.S. market under Breckenridge’s already-approved ANDA. Azacitidine is a generic equivalent of Vidaza[®], which is marketed by Celgene Corporation, U.S.

As per the terms of the agreement, Natco has provided the technology for manufacturing Azacitidine to Panacea Biotec’s facility located at Baddi, Himachal Pradesh, India. Panacea Biotec will be responsible for manufacture and supply of the product, which will be marketed, sold and distributed by Breckenridge in the U.S.


A copy of the Press Release being issued to the media, etc. in this regard is enclosed for your kind reference and record please.

Kindly acknowledge the receipt.

Thanking you,

Sincerely yours,

for **Panacea Biotec Ltd.**


Vinod Goel
Group CFO and Head Legal
& Company Secretary



Encl. As Above

B1 Extn. /G3, Mohan Co-op Indl. Estate,
Mathura Road, New Delhi -110044
Email: vinodgoel@panaceabiotec.com
Phone: D.I.D. +91-11-4167 9015
Fax: +91-11-4167 9070

Panacea Biotec Ltd.

CIN: L33117PB1984PLC022350

Registered Office: Ambala-Chandigarh Highway, Laru - 140 501, Punjab, India. Ph.: +91-1762-505900, Fax: +91-1762-505906.

e-mail: corporate@panaceabiotec.com website: www.panaceabiotec.com



Press Release

Panacea Biotec inks Tripartite Agreement with Natco Pharma Ltd. & Breckenridge Pharmaceutical Inc., for manufacturing and supply of Azacitidine injection in the U.S. market

New Delhi – 27th Aug 2018: Panacea Biotec, one of India's leading research based pharmaceutical and biotechnology companies, has entered into a tripartite agreement with Natco Pharma Ltd. ("Natco") and Breckenridge Pharmaceutical Inc. ("Breckenridge") for the manufacture and supply of Azacitidine Injection for the U.S. market under Breckenridge's already-approved ANDA. Azacitidine is a generic equivalent of Vidaza®, which is marketed by Celgene Corporation, U.S.

As per the terms of the agreement, Natco has provided the technology for manufacturing Azacitidine to Panacea Biotec's facility located at Baddi, Himachal Pradesh, India. Panacea Biotec will be responsible for manufacture and supply of the product, which will be marketed, sold and distributed by Breckenridge in the U.S.

The application (Prior Approval Supplement) for qualifying Panacea Biotec's site has been filed with the US FDA and approval is expected in due course of time.


Azacitidine is a nucleoside metabolic inhibitor indicated for the treatment of patients with the B myelodysplastic syndrome (MDS), having annual sales of about \$140 million USD as reported by IMS, MAT, Dec 2017.

Speaking on the occasion Dr. Rajesh Jain, Managing Director, Panacea Biotec said "We are excited about the collaboration with Natco and Breckenridge on Azacitidine. This collaboration will enable the company to grow its revenues and will also ensure increased capacity utilization of our state of the art oncology plant at Baddi "

About Panacea Biotec

Panacea Biotec is a leading pharmaceutical and biotechnology company with established Research, Manufacturing and Marketing capabilities. The Company is also amongst the top 15 pharmaceutical companies (AIOCD AWACS-MAT MAR-2017) in its represented market in India and amongst top 60 pharmaceutical Companies in India. The Company has been awarded twice (for 2015 & 2016) with the prestigious "India Innovation Award 2016 – Top 50" by Clarivate Analytics (Thomson Reuters).

CIN: L33117PB1984PLC022350
Corp Office: B-1 EXT. / A-27, MCIE, Mathura Road, New Delhi 110044, India;
Tel: +91 11 41679000, Extn. 1406; DID: +91 11 41578080, Fax: +91 11 41578002;
Mobile: +91 9312693040; Email: pdkaran@panaceabiotec.com ; Web: www.panaceabiotec.com



The product portfolio of includes highly innovative products in therapeutic areas of oncology, organ transplantation, nephrology, diabetes, osteoporosis, cardiovascular diseases and pediatric vaccines. It is working on a robust pipeline of high barrier to entry generics products, thus leveraging its capabilities in the areas of nanotechnology and platform drug delivery technologies like micro-particles, liposomes, gastro-retentive systems.

It has introduced its products in around 30 countries across the world, including USA, Germany and Russian Federation, through a combination of strategic collaborations and direct presence in select geographies. The Company has research collaborations with leading national and international research organizations and corporations.

The company's state-of-the-art manufacturing facilities for vaccines and pharmaceutical formulations comply with standards laid down by several leading regulatory agencies worldwide. The company has around 3000 employees including around 100 scientists working across 4 R&D centers of the Company.

About NATCO.

NATCO Pharma Ltd (NATCO), is a Hyderabad, India based R&D focused, vertically integrated pharmaceutical company with seven (7) manufacturing facilities, engaged in the development, manufacture and marketing of finished dosage formulations ("FDF") and active pharmaceutical ingredients ("APIs"). NATCO's products are sold in over 50 countries across the world. Apart from strong foundational business in India, NATCO's global presence is led through well known front end partners in the USA, EU and through our own brand footprint in our subsidiaries in Canada, Brazil and Singapore.

About Breckenridge

Breckenridge Pharmaceutical, Inc. is a privately-held own-label distributor that performs pharmaceutical marketing, research and development, as well as marketing and distribution in the U.S. The company was founded in 1983 and markets a broad range of generic prescription products in many therapeutic categories. The Breckenridge label is recognized by wholesalers, distributors, chains, and managed care accounts, as well as retail pharmacies nationwide. The company markets over 70 products in a variety of dosage forms including: tablets, capsules, soft gel capsules, liquids, suspensions, ophthalmics, nasal sprays, powders and injectable products. www.bpirx.com

For more information, please contact –



Mr. P. D. Karan

Vice President - Corporate Communication & Business Development

B-1 Extn. / A-27, Mohan Co-Operative Industrial Estate, Mathura Road, New Delhi – 110044, INDIA

Tel: + 91 11 41679000 Extn. 1406, 41578080 (Direct)

Fax + 91 11 41578002; Mobile: + 91 9312693040, + 91 9810500539

Email: pdkaran@panaceabiotec.com ; Web: www.panaceabiotec.com

CIN: L33117PB1984PLC022350

Corp Office: B-1 EXT. / A-27, MCIE, Mathura Road, New Delhi 110044, India;

Tel: +91 11 41679000, Extn. 1406; DID: +91 11 41578080, Fax: +91 11 41578002;

Mobile: +91 9312693040; Email: pdkaran@panaceabiotec.com ; Web: www.panaceabiotec.com

